Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02898792 · ClinicalTrials.gov registry record · Early Phase 1
Remifentanil in Adults With OSA
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 77
- Enrollment target
NCT02898792 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 77 participants.
The verdict
NCT02898792, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
Obstructive Sleep Apnea (OSA) is the most common problem that affects sleep. People with this problem have their airway blocked or minimized, causing snoring or gasping while sleeping. It can also reduce the amount of oxygen that circulates in the blood of people affected by it. Millions of Americans have OSA; 10% of adults have diagnosed OSA, an estimated 25% have undiagnosed OSA. There is concern in the medical community about how to manage pain in patients with OSA because of the risk of decreased or slower breathing associated with certain pain medications called opioids. Giving OSA patients opioids could cause them to have even lower oxygen amounts in their blood stream. It is conceivable that patients with OSA may require lower doses of opioids to cause decreased breathing as compared to patients without OSA, however this has not been proven. In this study, we are using a very short acting and easily reversible opioid pain medication called remifentanil in patients with OSA in order to find out if treated and untreated OSA patients respond to opioid differently than patients without OSA.
Interventions
- DRUG Targeted infusion of remifentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-09-16 |
| Est. Completion | 2018-05-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02898792
The ClinicalTrials.gov registry entry for NCT02898792 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Targeted infusion of remifentanil is the first listed.
NCT02898792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02898792 about?
NCT02898792 is a clinical study titled "Remifentanil in Adults With OSA". Obstructive Sleep Apnea (OSA) is the most common problem that affects sleep. People with this problem have their airway blocked or minimized, causing snoring or gasping while sleeping. It can also reduce the amount of oxygen that circulates in the blood of people affected by it. Millions of American...
What is the current status of trial NCT02898792?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 77 participants. The study started on 2016-09-16. Estimated completion is 2018-05-02.
What interventions are being tested in trial NCT02898792?
The interventions under investigation include: Targeted infusion of remifentanil (DRUG).
Who is sponsoring clinical trial NCT02898792?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.